Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
aTyr Pharma, Inc. (ATYR)
USD0.52
+0.03 (+7.06%)
US NASDAQ Healthcare Biotechnology
Address
10240 Sorrento Valley Road 92121
San Diego, CA, US
San Diego, CA, US
CEO
Sanjay S. Shukla
Website
atyrpharma.com
IPO
2015-05-07
CIK 1339970 ISIN US0021202025
Description
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.52
+0.03 (+7.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.54
Float Shares
95.61M
Free Float %
97.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -9.98% | -47.08% | -40.94% | -48.73% | -25.90% | -35.64% | -85.35% | -70.87% | -70.87% | -70.87% | -70.87% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Hold
Price Targets & DCF
Current price
0.52
Low
1.00
+92.2%
Consensus
5.13
+886.0%
Median
1.25
+140.2%
High
17.00
+3,167.3%
Ratings Trend (MoM)
33% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 6 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 4 |
5.13
+886.0%
|
| All Time | 4 |
5.13
+886.0%
|
Quality scores
Altman Z-Score
-11.66
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-19.2%
-
EPS growth Biotechnology: +29.7%+7.0% Q1'26: +35.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-36,156.8%
-
EBIT margin Biotechnology: +0.0%-40,856.3%
-
ROIC Biotechnology: -16.1%-12,244.0% Q1'26: -77.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+25.2% Q1'26: +13.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.16× Q1'26: -0.26× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 5 EPS Ana. |
Dec 2027 6 Rev. Ana. 5 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
422.0K
est: 431.8K (-2.3%)
|
10.46M
est: 8.53M (+22.5%)
|
—
est: 2.16M (-100.0%)
|
10.39M
est: 357.1K (+2,808.1%)
|
353.0K
est: 421.2K (-16.2%)
|
235.0K
est: 211.2K (+11.3%)
|
190.0K
est: 146.3K (+29.9%)
|
3.86M
3.86M – 3.86M
+2,535.9% YoY
|
8.79M
8.79M – 8.79M
+127.9% YoY
|
48.33M
48.33M – 48.33M
+449.9% YoY
|
155.96M
155.96M – 155.96M
+222.7% YoY
|
169.36M
169.36M – 169.36M
+8.6% YoY
|
| EBITDA |
-22.34M
est: -259.1K (-8,524.6%)
|
-14.65M
est: -5.12M (-186.0%)
|
-32.47M
est: -1.29M (-2,409.0%)
|
-44.71M
est: -214.3K (-20,764.3%)
|
-52.18M
est: -252.7K (-20,546.6%)
|
-66.37M
est: -126.7K (-52,283.0%)
|
-76.07M
est: -87.8K (-86,594.0%)
|
-2.31M
-2.31M – -2.31M
-2,535.9% YoY
|
-5.27M
-5.27M – -5.27M
-127.9% YoY
|
-29.00M
-29.00M – -29.00M
-449.9% YoY
|
-93.57M
-93.57M – -93.57M
-222.7% YoY
|
-101.62M
-101.62M – -101.62M
-8.6% YoY
|
| EBIT |
-22.98M
est: -259.1K (-8,769.8%)
|
-15.91M
est: -5.12M (-210.8%)
|
-33.78M
est: -1.29M (-2,509.7%)
|
-46.40M
est: -214.3K (-21,555.3%)
|
-54.92M
est: -252.7K (-21,631.2%)
|
-67.91M
est: -126.7K (-53,498.4%)
|
-77.63M
est: -87.8K (-88,363.8%)
|
-2.31M
-2.31M – -2.31M
-2,535.9% YoY
|
-5.27M
-5.27M – -5.27M
-127.9% YoY
|
-29.00M
-29.00M – -29.00M
-449.9% YoY
|
-93.57M
-93.57M – -93.57M
-222.7% YoY
|
-101.62M
-101.62M – -101.62M
-8.6% YoY
|
| Net Income |
-23.60M
est: -367.59M (+93.6%)
|
-16.22M
est: -160.90M (+89.9%)
|
-33.77M
est: -133.17M (+74.6%)
|
-45.34M
est: -135.16M (+66.5%)
|
-50.39M
est: -69.36M (+27.4%)
|
-64.02M
est: -84.70M (+24.4%)
|
-74.12M
est: -70.03M (-5.8%)
|
-54.16M
-55.33M – -52.99M
+22.7% YoY
|
-69.07M
-97.74M – -16.29M
-27.5% YoY
|
-69.26M
-84.56M – -8.27M
-0.3% YoY
|
-33.71M
-33.71M – -33.71M
+51.3% YoY
|
35.33M
35.33M – 35.33M
+204.8% YoY
|
| SGA |
9.35M
est: 8.50M (+10.0%)
|
9.08M
est: 168.01M (-94.6%)
|
10.75M
est: 42.47M (-74.7%)
|
12.29M
est: 7.03M (+74.7%)
|
12.98M
est: 8.29M (+56.5%)
|
13.78M
est: 8.03M (+71.5%)
|
17.60M
est: 5.56M (+216.3%)
|
146.64M
146.64M – 146.64M
+2,535.9% YoY
|
334.27M
334.27M – 334.27M
+127.9% YoY
|
1.84B
1.84B – 1.84B
+449.9% YoY
|
5.93B
5.93B – 5.93B
+222.7% YoY
|
6.44B
6.44B – 6.44B
+8.6% YoY
|
| EPS |
-7.03
est: -4.95 (-42.0%)
|
-1.77
est: -2.17 (+18.3%)
|
-1.77
est: -1.79 (+1.3%)
|
-1.60
est: -1.82 (+12.1%)
|
-0.94
est: -0.93 (-0.6%)
|
-0.86
est: -0.91 (+5.6%)
|
-0.80
est: -0.83 (+3.9%)
|
-0.59
-0.60 – -0.57
+29.5% YoY
|
-0.62
-1.05 – -0.18
-5.9% YoY
|
-0.49
-0.91 – -0.09
+21.1% YoY
|
-0.36
-0.36 – -0.36
+26.0% YoY
|
0.38
0.38 – 0.38
+204.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-63.11M
OE per share TTM
-0.68
Owner's Yield
-67.77%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
257.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
37
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2. | 18.15M | 6.70% | — | — | — | 18.15M | PN | Delaware | 2021-09-27 | ↗ |
| 2 | Jon M. Plexico | 9.85M | 11.00% | — | 9.85M | — | 9.85M | HC, IN | California | 2023-08-24 | ↗ |
| 3 | Stonepine Capital Management, LLC | 9.85M | 11.00% | — | 9.85M | — | 9.85M | IA, OO | California | 2023-08-24 | ↗ |
| 4 | Stonepine Capital, L.P. | 9.85M | 11.00% | — | 9.85M | — | 9.85M | PN | California | 2023-08-24 | ↗ |
| 5 | Timothy P. Lynch | 9.85M | 11.00% | — | 9.85M | — | 9.85M | HC, IN | California | 2023-08-24 | ↗ |
| 6 | but shall be subject to all other provisions of the Act (however, see the notes. | 9.13M | 6.90% | — | 8.75M | — | 8.75M | IA | — | 2024-02-08 | ↗ |
| 7 | CVI Investments, Inc. | 7.00M | 6.60% | — | 7.00M | — | 7.00M | CO | Cayman Islands | 2023-04-24 | ↗ |
| 8 | Heights Capital Management, Inc. | 7.00M | 6.60% | — | 7.00M | — | 7.00M | CO | Cayman Islands | 2023-04-24 | ↗ |
| 9 | Blank | 6.17M | 5.00% | — | 6.17M | — | 6.17M | IN | — | 2023-08-21 | ↗ |
| 10 | Master Fund, LP | 6.17M | 5.00% | — | 6.17M | — | 6.17M | PN | — | 2023-08-21 | ↗ |
| 11 | US Fund Management, Inc. | 6.17M | 5.00% | — | 6.17M | — | 6.17M | IA | — | 2023-08-21 | ↗ |
| 12 | Arsani William | 5.80M | 11.00% | — | 5.80M | — | 5.80M | HC, IN | United States | 2024-01-02 | ↗ |
| 13 | Logos GP LLC | 5.80M | 11.00% | — | 5.80M | — | 5.80M | OO | Delaware | 2024-01-02 | ↗ |
| 14 | Logos Global Management GP LLC | 5.80M | 11.00% | — | 5.80M | — | 5.80M | HC, OO | Delaware | 2024-01-02 | ↗ |
| 15 | Logos Global Management LP | 5.80M | 11.00% | — | 5.80M | — | 5.80M | IA, PN | Delaware | 2024-01-02 | ↗ |
| 16 | Logos Global Master Fund LP | 5.80M | 11.00% | — | 5.80M | — | 5.80M | PN | Cayman Islands | 2024-01-02 | ↗ |
| 17 | Point72 Asset Management, L.P. | 5.04M | 6.20% | — | 5.04M | — | — | PN | Delaware | 2024-10-15 | ↗ |
| 18 | Point72 Capital Advisors, Inc. | 5.04M | 6.20% | — | 5.04M | — | — | CO | Delaware | 2024-10-15 | ↗ |
| 19 | Steven A. Cohen | 5.04M | 6.20% | — | 5.04M | — | — | IN | Delaware | 2024-10-15 | ↗ |
| 20 | Highbridge Capital Management, LLC | 4.86M | 7.64% | — | 4.86M | — | — | IA, OO | — | 2022-02-11 | ↗ |
| 21 | Laurence W. Lytton | 4.44M | 11.00% | 4.44M | 5.0K | 4.44M | 5.0K | IN | USA | 2023-02-22 | ↗ |
| 22 | Koh, Bong | 1.57M | 5.60% | — | 1.57M | — | — | IN | United States | 2022-02-14 | ↗ |
| 23 | Shah, Nimish | 1.57M | 5.60% | — | 1.57M | — | — | IN | United States | 2022-02-14 | ↗ |
| 24 | VHCP Co-Investment Holdings II, LLC | 1.57M | 5.60% | — | 1.57M | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 25 | VHCP Co-Investment Holdings III, LLC | 1.57M | 5.60% | — | 1.57M | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 26 | VHCP Management EG, LLC | 1.57M | 5.60% | — | 1.57M | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 27 | VHCP Management II, LLC | 1.57M | 5.60% | — | 1.57M | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 28 | VHCP Management III, LLC | 1.57M | 5.60% | — | 1.57M | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 29 | Venrock Healthcare Capital Partners EG, L.P. | 1.57M | 5.60% | — | 1.57M | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 30 | Venrock Healthcare Capital Partners II, L.P. | 1.57M | 5.60% | — | 1.57M | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 31 | Venrock Healthcare Capital Partners III, L.P. | 1.57M | 5.60% | — | 1.57M | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 32 | Chart Westcott | 35.0K | 0.10% | — | 35.0K | — | 35.0K | HC, IN | Delaware | 2022-02-14 | ↗ |
| 33 | Ikarian Capital, LLC | 35.0K | 0.10% | — | 35.0K | — | 35.0K | IA | Delaware | 2022-02-14 | ↗ |
| 34 | Neil Shahrestani | 35.0K | 0.10% | — | 35.0K | — | 35.0K | HC, IN | Delaware | 2022-02-14 | ↗ |
| 35 | Consonance Capital Management LP | — | 0.00% | — | — | — | — | IA, PN | — | 2022-02-14 | ↗ |
| 36 | Consonance Capman GP LLC | — | 0.00% | — | — | — | — | HC, OO | — | 2022-02-14 | ↗ |
| 37 | Mitchell Blutt | — | 0.00% | — | — | — | — | HC, IN | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 26 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Russell 2000 Growth ETF VTWG | 0.00% | 46.3K | 0.06% |
| 2 | Vanguard Russell 2000 ETF VTWO | 0.00% | 258.9K | 0.06% |
| 3 | Vanguard Extended Market ETF VXF | 0.00% | 559.2K | 0.05% |
| 4 | Vanguard Russell 3000 ETF VTHR | 0.00% | 4.0K | 0.06% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.0K | 0.03% |
| 6 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 8.4K | 0.17% |
| 7 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 618.09 | 0.17% |
| 8 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.43M | 0.03% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.1K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.7K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
6
Sells
6
Shares acquired
2.34M
Shares disposed
23.2K
Cash buys
—
Cash sales
3.00
Net activity
+2,318,579
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-04 | Shukla Sanjay | Director / Officer | S-Sale | D | Common Stock | 3,745 | 0.98 | 3.7K | 153,553 | D | ↗ |
| 2026-02-04 | DENYES NANCY | Officer | S-Sale | D | Common Stock | 1,118 | 0.98 | 1.1K | 33,124 | D | ↗ |
| 2026-02-04 | Broadfoot Jill Marie | Officer | S-Sale | D | Common Stock | 1,558 | 0.98 | 1.5K | 37,296 | D | ↗ |
| 2026-02-03 | Shukla Sanjay | Director / Officer | M-Exempt | A | Common Stock | 10,375 | 0.00 | — | 157,298 | D | ↗ |
| 2026-02-03 | DENYES NANCY | Officer | M-Exempt | A | Common Stock | 2,687 | 0.00 | — | 34,242 | D | ↗ |
| 2026-02-03 | Broadfoot Jill Marie | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 38,854 | D | ↗ |
| 2026-01-09 | Shukla Sanjay | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,500,000 | 0.71 | 1.07M | 1,500,000 | D | ↗ |
| 2026-01-09 | DENYES NANCY | Officer | A-Award | A | Employee Stock Options (right to buy) | 412,500 | 0.71 | 294.0K | 412,500 | D | ↗ |
| 2026-01-09 | Broadfoot Jill Marie | Officer | A-Award | A | Employee Stock Option (right to buy) | 412,500 | 0.71 | 294.0K | 412,500 | D | ↗ |
| 2025-10-09 | SCHIMMEL PAUL | Director | P-Purchase | A | Common Stock | 317,999 | 0.94 | 299.4K | 1,413,023 | I | ↗ |
| 2025-10-08 | SCHIMMEL PAUL | Director | P-Purchase | A | Common Stock | 682,001 | 0.90 | 612.4K | 1,095,024 | I | ↗ |
| 2025-05-01 | Zaknoen Sara | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.34 | 167.0K | 50,000 | D | ↗ |
| 2025-05-01 | SCHIMMEL PAUL | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.34 | 167.0K | 50,000 | D | ↗ |
| 2025-05-01 | Lucas Svetlana | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.34 | 167.0K | 50,000 | D | ↗ |
| 2025-05-01 | Gross Jane A | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.34 | 167.0K | 50,000 | D | ↗ |
| 2025-05-01 | COUGHLIN TIMOTHY | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.34 | 167.0K | 50,000 | D | ↗ |
| 2025-05-01 | BENEVICH ERIC | Director | A-Award | A | Stock Option (right to buy) | 50,000 | 3.34 | 167.0K | 50,000 | D | ↗ |
| 2025-03-17 | Gross Jane A | Director | P-Purchase | A | Common Stock | 3,750 | 4.00 | 15.0K | 9,750 | D | ↗ |
| 2025-02-04 | DENYES NANCY | Officer | S-Sale | D | Common Stock | 899 | 3.78 | 3.4K | 26,555 | D | ↗ |
| 2025-02-04 | Broadfoot Jill Marie | Officer | S-Sale | D | Common Stock | 1,254 | 3.78 | 4.7K | 31,763 | D | ↗ |
| 2025-02-03 | Shukla Sanjay | Director / Officer | M-Exempt | A | Common Stock | 10,375 | 0.00 | — | 146,923 | D | ↗ |
| 2025-02-03 | DENYES NANCY | Officer | M-Exempt | A | Common Stock | 2,687 | 0.00 | — | 27,454 | D | ↗ |
| 2025-02-03 | Broadfoot Jill Marie | Officer | M-Exempt | A | Common Stock | 3,750 | 0.00 | — | 33,017 | D | ↗ |
| 2025-01-08 | Shukla Sanjay | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 1,000,000 | 3.74 | 3.74M | 1,000,000 | D | ↗ |
| 2025-01-08 | DENYES NANCY | Officer | A-Award | A | Employee Stock Option (right to buy) | 275,000 | 3.74 | 1.03M | 275,000 | D | ↗ |
| 2025-01-08 | Broadfoot Jill Marie | Officer | A-Award | A | Employee Stock Option (right to buy) | 275,000 | 3.74 | 1.03M | 275,000 | D | ↗ |
| 2024-12-10 | BENEVICH ERIC | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-07-24 | SCHIMMEL PAUL | Director | P-Purchase | A | Common Stock | 52,300 | 1.93 | 101.0K | 413,023 | — | ↗ |
| 2024-07-23 | SCHIMMEL PAUL | Director | P-Purchase | A | Common Stock | 6,648 | 1.82 | 12.1K | 360,723 | — | ↗ |
| 2024-07-22 | SCHIMMEL PAUL | Director | P-Purchase | A | Common Stock | 41,052 | 1.74 | 71.5K | 354,075 | — | ↗ |
| 2024-06-05 | DENYES NANCY | Officer | P-Purchase | A | Common Stock | 5,000 | 1.86 | 9.3K | 22,267 | — | ↗ |
| 2017-11-13 | EcoR1 Capital Fund Qualified, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,083 | 3.95 | 4.3K | 3,209,316 | — | ↗ |
| 2017-11-10 | EcoR1 Capital Fund Qualified, L.P. | 10% Owner | S-Sale | D | Common Stock | 5,860 | 4.00 | 23.4K | 3,210,399 | — | ↗ |
| 2017-11-09 | EcoR1 Capital Fund Qualified, L.P. | 10% Owner | S-Sale | D | Common Stock | 5,819 | 4.15 | 24.2K | 3,216,259 | — | ↗ |
| 2017-11-08 | EcoR1 Capital Fund Qualified, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,070 | 4.30 | 4.6K | 3,222,078 | — | ↗ |
| 2017-11-01 | EcoR1 Capital Fund Qualified, L.P. | 10% Owner | P-Purchase | A | Common Stock | 24,728 | 4.80 | 118.7K | 3,223,148 | — | ↗ |
| 2017-10-01 | EcoR1 Capital Fund Qualified, L.P. | 10% Owner | P-Purchase | A | Common Stock | 4,879 | 5.05 | 24.6K | 3,198,420 | — | ↗ |
| 2017-08-28 | EcoR1 Capital Fund Qualified, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 3,193,541 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-13.9K
Shares Outstanding
98.05M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Sanjay S. Shukla, M.D., M.S. President and CEO | 639.0K | — | — | 2.60M | 210.9K | 11.2K | 3.46M | 75.09% | ↗ |
| 2 | 2025 | Jill M. Broadfoot Chief Financial Officer | 471.8K | — | — | 713.7K | 113.2K | 11.2K | 1.31M | 54.48% | ↗ |
| 3 | 2025 | Nancy E. Denyes General Counsel | 451.6K | — | — | 713.7K | 108.4K | 11.2K | 1.28M | 55.55% | ↗ |
| 4 | 2024 | Sanjay S. Shukla, M.D., M.S. President and CEO | 580.9K | — | — | 641.8K | 246.9K | 11.0K | 1.48M | 43.35% | ↗ |
| 5 | 2024 | Jill M. Broadfoot Chief Financial Officer | 428.9K | — | — | 160.4K | 145.8K | 11.0K | 746.2K | 21.50% | ↗ |
| 6 | 2024 | Nancy E. Denyes General Counsel | 410.5K | — | — | 160.4K | 139.6K | 18.8K | 729.3K | 22.00% | ↗ |
| 7 | 2023 | Sanjay S. Shukla, M.D., M.S. President and CEO | 561.2K | — | — | 532.3K | 196.4K | 10.5K | 1.30M | 40.93% | ↗ |
| 8 | 2023 | Jill M. Broadfoot Chief Financial Officer | 414.4K | — | — | 133.1K | 116.0K | 14.3K | 677.8K | 19.63% | ↗ |
| 9 | 2023 | Nancy E. Denyes General Counsel | 396.6K | — | — | 133.1K | 111.1K | 10.5K | 651.3K | 20.43% | ↗ |
| 10 | 2022 | Sanjay S. Shukla, M.D., M.S. President and CEO | 561.2K | — | 229.1K | 1.39M | 224.5K | 9.7K | 2.41M | 67.01% | ↗ |
| 11 | 2022 | Jill M. Broadfoot Chief Financial Officer | 414.4K | — | 82.8K | 274.1K | 132.6K | 9.6K | 913.5K | 39.07% | ↗ |
| 12 | 2022 | Nancy E. Denyes General Counsel | 396.6K | — | 59.3K | 266.1K | 126.9K | 8.6K | 857.5K | 37.95% | ↗ |
| 13 | 2021 | Sanjay S. Shukla, M.D., M.S. President and CEO | 510.2K | — | — | 1.08M | 293.4K | 12.8K | 1.89M | 56.87% | ↗ |
| 14 | 2021 | Jill M. Broadfoot Chief Financial Officer | 376.7K | — | — | 355.7K | 173.3K | 11.8K | 917.4K | 38.77% | ↗ |
| 15 | 2021 | Nancy E. Denyes General Counsel | 360.6K | — | — | 353.7K | 165.9K | 11.1K | 891.3K | 39.68% | ↗ |
| 16 | 2020 | Sanjay S. Shukla, M.D., M.S. President and CEO | 470.3K | — | — | 381.8K | 223.4K | 8.4K | 1.08M | 35.23% | ↗ |
| 17 | 2020 | Jill M. Broadfoot Chief Financial Officer | 365.8K | — | — | 182.7K | 139.0K | 11.4K | 698.8K | 26.14% | ↗ |
| 18 | 2020 | Nancy E. Denyes General Counsel | 350.1K | — | — | 148.1K | 116.4K | 10.7K | 625.3K | 23.69% | ↗ |
| 19 | 2019 | Sanjay S. Shukla, M.D., M.S. President and Chief Executive Officer | 450.0K | — | 25.9K | 82.4K | 95.6K | 10.1K | 664.0K | 16.31% | ↗ |
| 20 | 2019 | Sanjay S. Shukla, M.D., M.S. President and CEO | 450.0K | — | 25.9K | 82.4K | 95.6K | 10.1K | 664.0K | 16.31% | ↗ |
| 21 | 2019 | Jill M. Broadfoot Chief Financial Officer | 350.0K | — | 12.9K | 20.6K | 59.5K | 11.6K | 454.6K | 7.38% | ↗ |
| 22 | 2019 | Nancy E. Denyes General Counsel | 335.0K | — | — | 51.5K | 49.8K | 12.9K | 449.3K | 11.46% | ↗ |
| 23 | 2018 | Sanjay S. Shukla, M.D., M.S. President and Chief Executive Officer | 450.0K | — | — | 780.0K | 140.5K | 9.9K | 1.38M | 56.50% | ↗ |
| 24 | 2018 | Sanjay S. Shukla, M.D., M.S. President and CEO | 450.0K | — | — | 780.0K | 140.5K | 9.9K | 1.38M | 56.50% | ↗ |
| 25 | 2018 | Ashraf Amanullah, Ph.D. Former Senior Vice President, Biologics, Development and Manufacturing | 135.4K | — | — | 260.0K | — | 377.1K | 772.5K | 33.66% | ↗ |
| 26 | 2018 | David J. King, Ph.D. Former Chief Scientific Officer | 304.6K | — | — | 390.0K | — | 22.7K | 717.3K | 54.37% | ↗ |
| 27 | 2018 | Jill M. Broadfoot Chief Financial Officer | 148.5K | — | — | 121.9K | 58.3K | 5.4K | 334.1K | 36.48% | ↗ |
| 28 | 2017 | John D. Mendlein, Ph.D. Former CEO/Current Director | 518.2K | — | — | 2.41M | 165.8K | 20.6K | 3.12M | 77.40% | ↗ |
| 29 | 2017 | Sanjay S. Shukla, M.D., M.S. President and CEO | 402.8K | — | — | 1.62M | 131.6K | 9.8K | 2.16M | 74.85% | ↗ |
| 30 | 2017 | Sanuj K. Ravindran, M.D. Former Chief Business Officer | 384.3K | — | — | 412.5K | — | 386.7K | 1.18M | 34.85% | ↗ |
| 31 | 2017 | David J. King, Ph.D. Chief Scientific Officer | 300.0K | — | — | 174.0K | 68.3K | 7.1K | 549.4K | 31.67% | ↗ |
| 32 | 2017 | David J. King, Ph.D. Former Chief Scientific Officer | 300.0K | — | — | 174.0K | 68.3K | 7.1K | 549.4K | 31.67% | ↗ |
| 33 | 2016 | Sanuj K. Ravindran, M.D. Former Chief Business Officer | 373.8K | 25.0K | — | 1.10M | 75.0K | 91.4K | 1.66M | 65.98% | ↗ |
| 34 | 2016 | Sanuj K. Ravindran, M.D. Chief Business Officer | 373.8K | 25.0K | — | 1.10M | 75.0K | 91.4K | 1.66M | 65.98% | ↗ |
| 35 | 2016 | John D. Mendlein, Ph.D. Chief Executive Officer and Director | 494.7K | — | — | 865.8K | 192.9K | 16.0K | 1.57M | 55.17% | ↗ |
| 36 | 2016 | John D. Mendlein, Ph.D. Former CEO/Current Director | 494.7K | — | — | 865.8K | 192.9K | 16.0K | 1.57M | 55.17% | ↗ |
| 37 | 2016 | Sanjay S. Shukla, M.D., M.S. President and CEO | 284.1K | 31.3K | — | 612.9K | 87.8K | 80.4K | 1.10M | 55.90% | ↗ |
| 38 | 2016 | Sanjay S. Shukla, M.D., M.S. Chief Medical Officer | 284.1K | 31.3K | — | 612.9K | 87.8K | 80.4K | 1.10M | 55.90% | ↗ |
| 39 | 2015 | John D. Mendlein, Ph.D. Chief Executive Officer and Director | 472.8K | — | — | 3.23M | 210.4K | 14.1K | 3.93M | 82.25% | ↗ |
| 40 | 2015 | Kelly Blackburn Vice President, Clinical Affairs | 295.0K | — | — | 882.1K | 78.8K | 9.9K | 1.27M | 69.69% | ↗ |
| 41 | 2015 | David M. Weiner, M.D. Former Chief Medical Officer | 273.6K | — | — | 646.5K | — | 124.6K | 1.04M | 61.88% | ↗ |
| 42 | 2015 | Melissa A. Ashlock, M.D. Former Senior Vice President Translational Medicine and Therapeutics | 291.2K | — | — | 642.6K | 84.1K | 5.8K | 1.02M | 62.77% | ↗ |
| 43 | 2014 | David M. Weiner, M.D. Former Chief Medical Officer | 265.2K | — | — | 1.47M | 31.3K | 75.2K | 1.84M | 79.82% | ↗ |
| 44 | 2014 | John D. Mendlein, Ph.D. Chief Executive Officer and Director | 410.0K | — | 268.1K | 604.6K | 76.9K | 38.4K | 1.40M | 62.43% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sanjay S. Shukla | President, Chief Executive Officer & Director | 861.1K | — |
| Jill Broadfoot | Chief Financial Officer | 596.2K | female |
| Nancy E. Denyes Krueger | General Counsel & Corporate Secretary | 571.2K | female |
| Ashlee Dunston | Director of Investor Relations & Corporate Communications | — | female |
| Peter Villiger | Vice President of Corporate Development | — | male |
| Leslie Nangle | Vice President of Research | — | — |
| Dalia R. Rayes | Head of Commercial, Global Efzofitimod Franchise | — | female |
| Danielle Campbell | Vice President of Human Resource | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ATYR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
